
 
 
 
 
 
 
 
 
   
 1. the AIMP2DX2 protein that comprises the AIMP2 aminoacid sequence, the exon 2 zone of wherein said AIMP2 aminoacid sequence is deleted. 
 
     
 
   
 
 2. AIMP2DX2 protein according to claim 1, wherein said AIMP2DX2 protein comprises the aminoacid sequence of SEQID NO:2. 
 
     
 
   
 
 3. AIMP2DX2 protein according to claim 1, wherein said AIMP2DX2 protein is used as cancer markers. 
 
     
 4. the nucleic acid molecule that comprises the proteinic nucleotide sequence of the coding described AIMP2DX2 of claim 1. 
 
     
 
   
 
 5. nucleic acid molecule according to claim 4, wherein said nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO:1. 
 
     
 6. recombinant vectors, the nucleic acid molecule in this recombinant vectors comprise the proteinic nucleotide sequence of the coding described AIMP2DX2 of claim 1. 
 
     
 7. transformant, this transformant transforms with the described recombinant vectors of claim 6. 
 
     
 
   
 
 8. one kind prepares the described AIMP2DX2 method of protein of claim 1, comprises to cultivate the described transformant of claim 7. 
 
     
 
   
 
 9. one kind is specific to the proteinic antibody of the described AIMP2DX2 of claim 1. 
 
     
 10. cancer diagnosing kit, this test kit comprise and are specific to the proteinic antibody of the described AIMP2DX2 of claim 1. 
 
     
 11. a screening wherein comprises following steps as the AIMP2DX2 method of protein of cancer markers: 
 (a) provide testing sample; With 
 (b) expression of the proteinic nucleotide sequence of the coding described AIMP2DX2 of claim 1 in the described sample of detection, the detection indication of the expression of the proteinic described nucleotide sequence of described AIMP2DX2 of wherein encoding has cancer. 
 
     
 
   
 
 12., wherein detect described in the step (b) by making described sample and being specific to the proteinic antibody of the described AIMP2DX2 of claim 1 and contacting and carry out according to the method for claim 11. 
 
     
 
   
 
 13., wherein detect described in the step (b) and undertaken by amplified reaction or hybridization according to the method for claim 11. 
 
     
 
   
 
 14. the RT-PCR (reverse transcription polymerase chain reaction) of the primer of method according to claim 13, the wherein said amplified reaction mRNA by using the mRNA can distinguish AIMP2DX2 and AIMP2 carries out or the probe of the mRNA of described hybridization by using the mRNA that can distinguish AIMP2DX2 and AIMP2 carries out. 
 
     
 
   
 
 15. method according to claim 13, the sequence of wherein said primer comprise SEQ ID No.5 and 6, SEQID No.7 and 8 or SEQ ID No.16 and 6; Or the sequence of described probe comprises SEQ ID No.8 or 16. 
 
     
 16. nucleic acid molecule that comprises SEQ ID No.3,4,5,6,7,8 or 16 nucleotide sequence. 
 
     
 
   
 
 17. be specific to the siRNA nucleic acid molecule of the proteinic mRNA of the described AIMP2DX2 of claim 1. 
 
     
 
   
 
 18. siRNA nucleic acid molecule according to claim 17, wherein said siRNA nucleic acid molecule comprise coding SEQID Nos.9 and 10, SEQ ID Nos.11 and 12 or the nucleotide sequence of SEQ ID Nos.13 and 14 justice and sense-rna arranged. 
 
     
 19. a pharmaceutical compositions for the treatment of cancer wherein comprises the described siRNA nucleic acid molecule of claim 17. 
 
     
 20. a treatment method for cancer wherein comprises and uses the described siRNA nucleic acid molecule of claim 17. 
 
     
 21. an antisense oligonucleotide, the proteinic mRNA of the described AIMP2DX2 of this oligonucleotide and claim 1 zone is a complementary. 
 
     
 22. a pharmaceutical compositions for the treatment of cancer wherein comprises the described antisense oligonucleotide of claim 21. 
 
     
 23. a treatment method for cancer wherein comprises and uses the described antisense oligonucleotide of claim 21. 
 
     
 24. a method of screening cancer therapy drug, described cancer therapy drug suppresses the formation of heterodimer between described AIMP2DX2 protein of claim 1 and AIMP2 protein, comprises following steps: 
 (a) make test substances and comprise described AIMP2DX2 protein and contact with the proteinic composition of described AIMP2; With 
 (b) determine whether described test substances suppresses the formation of the described heterodimer between described AIMP2DX2 protein and described AIMP2 protein, 
 The described test substances that wherein suppresses the described heterodimer formation between described AIMP2DX2 protein and described AIMP2 protein is be evaluated as cancer therapy drug. 
 
     
 
   
 
 25. according to the method for claim 24, wherein this method is estimated method by yeast two-hybrid assay method or external pull-down and is carried out. 
 
     
 26. a method of screening cancer therapy drug, described cancer therapy drug suppresses the described AIMP2DX2 expression of gene of claim 1 or promotes the proteinic destruction of described AIMP2DX2, comprises following steps: 
 (a) make test substances and the cells contacting of expressing described AIMP2DX2 gene; With 
 (b) determine whether described test substances suppresses described AIMP2DX2 expression of gene or promote the proteinic destruction of described AIMP2DX2, 
 The described test substances of the described AIMP2DX2 genetic expression of wherein said inhibition is be evaluated as cancer therapy drug. 
 
     
 
   
 
 27. according to the method for claim 26, wherein this method is undertaken by RT-PCR or Western blotting. 
 
   
 
 
 
 
 
 
 
 
